- Home
- LEU vs XNCR Comparison
LEU vs XNCR Comparison
Compare LEU & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEU
- XNCR
- Stock Information
- Founded
- LEU 1998
- XNCR 1997
- Country
- LEU United States
- XNCR United States
- Employees
- LEU N/A
- XNCR N/A
- Industry
- LEU Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- LEU Industrials
- XNCR Health Care
- Exchange
- LEU Nasdaq
- XNCR Nasdaq
- Market Cap
- LEU 1.3B
- XNCR 1.3B
- IPO Year
- LEU 1998
- XNCR 2013
- Fundamental
- Price
- LEU $98.60
- XNCR $15.74
- Analyst Decision
- LEU Buy
- XNCR Strong Buy
- Analyst Count
- LEU 2
- XNCR 8
- Target Price
- LEU $92.00
- XNCR $34.63
- AVG Volume (30 Days)
- LEU 1.0M
- XNCR 455.5K
- Earning Date
- LEU 02-06-2025
- XNCR 03-04-2025
- Dividend Yield
- LEU N/A
- XNCR N/A
- EPS Growth
- LEU N/A
- XNCR N/A
- EPS
- LEU 4.47
- XNCR N/A
- Revenue
- LEU $442,000,000.00
- XNCR $85,164,000.00
- Revenue This Year
- LEU N/A
- XNCR N/A
- Revenue Next Year
- LEU $3.57
- XNCR $80.86
- P/E Ratio
- LEU $21.98
- XNCR N/A
- Revenue Growth
- LEU 38.04
- XNCR N/A
- 52 Week Low
- LEU $33.51
- XNCR $15.31
- 52 Week High
- LEU $122.95
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- LEU 52.64
- XNCR 21.76
- Support Level
- LEU $111.78
- XNCR $15.53
- Resistance Level
- LEU $122.95
- XNCR $16.69
- Average True Range (ATR)
- LEU 9.15
- XNCR 0.76
- MACD
- LEU -0.34
- XNCR 0.04
- Stochastic Oscillator
- LEU 47.00
- XNCR 9.57
About LEU Centrus Energy Corp.
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.